Literature DB >> 25199779

Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis.

Michael J Dolton1, Roger J M Brüggemann2, David M Burger2, Andrew J McLachlan3.   

Abstract

Posaconazole oral suspension is widely used for antifungal prophylaxis and treatment in immunocompromised patients, with highly variable pharmacokinetics reported in patients due to inconsistent oral absorption. This study aimed to characterize the pharmacokinetics of posaconazole in adults and investigate factors that influence posaconazole pharmacokinetics byusing a population pharmacokinetic approach. Nonlinear mixed-effects modeling was undertaken for two posaconazole studies in patients and healthy volunteers. The influences of demographic and clinical characteristics, such as mucositis, diarrhea, and drug-drug interactions, on posaconazole pharmacokinetics were investigated using a stepwise forward inclusion/backwards deletion procedure. A total of 905 posaconazole concentration measurements from 102 participants were analyzed. A one-compartment pharmacokinetic model with first-order oral absorption with lag time and first-order elimination best described posaconazole pharmacokinetics. Posaconazole relative bioavailability was 55% lower in patients who received posaconazole than in healthy volunteers. Coadministration of proton pump inhibitors (PPIs) or metoclopramide, as well as the occurrence of mucositis or diarrhea, reduced posaconazole relative bioavailability by 45%, 35%, 58%, and 45%, respectively, whereas concomitant ingestion of a nutritional supplement significantly increased bioavailability (129% relative increase). Coadministration of rifampin or phenytoin increased apparent posaconazole clearance by more than 600%, with a smaller increase observed with fosamprenavir (34%). Participant age, weight, or sex did not significantly affect posaconazole pharmacokinetics. Posaconazole absorption was reduced by a range of commonly coadministered medicines and clinical complications, such as mucositis and diarrhea. Avoidance of PPIs and metoclopramide and administration with food or a nutritional supplement are effective strategies to increase posaconazole absorption.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25199779      PMCID: PMC4249414          DOI: 10.1128/AAC.03777-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  42 in total

1.  Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.

Authors:  A J Ullmann; O A Cornely; A Burchardt; R Hachem; D P Kontoyiannis; K Töpelt; R Courtney; D Wexler; G Krishna; M Martinho; G Corcoran; I Raad
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.

Authors:  Oliver A Cornely; Johan Maertens; Drew J Winston; John Perfect; Andrew J Ullmann; Thomas J Walsh; David Helfgott; Jerzy Holowiecki; Dick Stockelberg; Yeow-Tee Goh; Mario Petrini; Cathy Hardalo; Ramachandran Suresh; David Angulo-Gonzalez
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

3.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

4.  Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations.

Authors:  Farkad Ezzet; David Wexler; Rachel Courtney; Gopal Krishna; Josephine Lim; Mark Laughlin
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

5.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.

Authors:  Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect
Journal:  Clin Infect Dis       Date:  2006-11-28       Impact factor: 9.079

6.  Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men.

Authors:  G Krishna; A Parsons; B Kantesaria; T Mant
Journal:  Curr Med Res Opin       Date:  2007-03       Impact factor: 2.580

7.  Inducing properties of rifampicin and rifabutin for selected enzyme activities of the cytochrome P-450 and UDP-glucuronosyltransferase superfamilies in female rat liver.

Authors:  F Oesch; M Arand; M S Benedetti; M G Castelli; P Dostert
Journal:  J Antimicrob Chemother       Date:  1996-06       Impact factor: 5.790

8.  Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men.

Authors:  Gopal Krishna; Angela Sansone-Parsons; Bhavna Kantesaria
Journal:  Curr Med Res Opin       Date:  2007-05-11       Impact factor: 2.580

9.  Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil).

Authors:  Anima Ghosal; Neil Hapangama; Yuan Yuan; Joana Achanfuo-Yeboah; Robert Iannucci; Swapan Chowdhury; Kevin Alton; James E Patrick; Shmuel Zbaida
Journal:  Drug Metab Dispos       Date:  2004-02       Impact factor: 3.922

10.  Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease.

Authors:  Gopal Krishna; Monika Martinho; Pranatharthi Chandrasekar; Andrew J Ullmann; Hernando Patino
Journal:  Pharmacotherapy       Date:  2007-12       Impact factor: 4.705

View more
  26 in total

1.  Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.

Authors:  Elodie Gautier-Veyret; Léa Bolcato; Matthieu Roustit; Stéphanie Weiss; Julia Tonini; Marie-Pierre Brenier-Pinchart; Muriel Cornet; Anne Thiebaut-Bertrand; Françoise Stanke-Labesque
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

2.  Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.

Authors:  A Petitcollin; C Boglione-Kerrien; C Tron; S Nimubona; S Lalanne; F Lemaitre; E Bellissant; M-C Verdier
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

3.  Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review.

Authors:  T Jancel; P A Shaw; C W Hallahan; T Kim; A F Freeman; S M Holland; S R Penzak
Journal:  J Clin Pharm Ther       Date:  2016-12-16       Impact factor: 2.512

4.  Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.

Authors:  Urshila Durani; Pritish K Tosh; Jason N Barreto; Lynn L Estes; Paul J Jannetto; Aaron J Tande
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

5.  Antifungal Prophylaxis With Posaconazole in Immunocompromised Children Younger Than 13 Years.

Authors:  Julio Maquera-Afaray; Medalit Luna-Vilchez; Blanca Salazar-Mesones; Diana Portillo-Alvarez; Luis Uribe-Ramirez; Graciela Taipe-Sedano; Carlos Santillán-Salas; José W López
Journal:  J Pediatr Pharmacol Ther       Date:  2021-12-22

6.  Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.

Authors:  Kim Vanstraelen; Juergen Prattes; Johan Maertens; Katrien Lagrou; Hélène Schoemans; Nele Peersman; Pieter Vermeersch; Koen Theunissen; Raf Mols; Patrick Augustijns; Pieter Annaert; Martin Hoenigl; Isabel Spriet
Journal:  Eur J Clin Pharmacol       Date:  2016-04-11       Impact factor: 2.953

7.  Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.

Authors:  David J Epstein; Susan K Seo; Yao-Ting Huang; Jay H Park; Virginia M Klimek; Ellin Berman; Martin S Tallman; Mark G Frattini; Genovefa A Papanicolaou
Journal:  J Infect       Date:  2018-05-07       Impact factor: 6.072

Review 8.  Fundament and Prerequisites for the Application of an Antifungal TDM Service.

Authors:  Roger J M Brüggemann; Rob E Aarnoutse
Journal:  Curr Fungal Infect Rep       Date:  2015

Review 9.  Therapeutic Drug Monitoring of Posaconazole: an Update.

Authors:  Bart G J Dekkers; Martijn Bakker; Kim C M van der Elst; Marieke G G Sturkenboom; Anette Veringa; Lambert F R Span; Jan-Willem C Alffenaar
Journal:  Curr Fungal Infect Rep       Date:  2016-05-07

Review 10.  Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.

Authors:  Zorica Jović; Slobodan M Janković; Dejana Ružić Zečević; Dragan Milovanović; Srđan Stefanović; Marko Folić; Jasmina Milovanović; Marina Kostić
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.569

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.